Drug Treatment Profile among Outpatients of Type 2 Diabetes Melitus after Implemented of JKN

  • MITA RESTINIA UNIVERSITAS PANCASILA
  • YUSI ANGGRIANI UNIVERSITAS PANCASILA
  • TRI KUSUMAENI UNIVERSITAS PANCASILA
  • ARIES MERYTA UNIVERSITAS PANCASILA

Abstract

In 2014, health insurance entirely colected together into Badan Penyelenggara Jaminan Sosial (BPJS) became Jaminan Kesehatan Nasional (JKN). But there is different payment method that is ASKES used Fee for Services (FFS) method and BPJS use INA-CBGs method.  Diabetes mellitus is a chronic disease that patients with that diagnosed should use drug continuously. Therefore, research with conducted by time series longitudinal retrospective method that aimed to observe impact of JKN about drug treatment profile among outpatients of  type 2 DM in X Hospital Jakarta. Total of samples collected were 84 patients, 31 (36.90%) of male and  53 (63.10%) of female. Most patients (29.76%) were 66-70 years old. There were 38 patients with 10 times of visite, 27 patients with 11 times of visite, 19 patients with 12 times of visit. Based on drug treatment profile, after JKN has launched, decreasing of total of drug use, number of visit increased to 42 visits, kinds of drug appropriate with DPHO decreased until 79%, kinds of drug appropriate with national formularium rised 97%, generic drugs also increased 54% and non generic drug decreased 47%. Based on descriptive analysis, when JKN has launched, there were impact toward drug treatment profile.

References

1. Peraturan Presiden Republik Indonesia. No 111. Jaminan Kesehatan Nasional. 2013.
2. Kementrian Kesehatan Republik Indonesia, Bahan paparan Jaminan kesehatan nasional dalam SJSN. 2013.
3. Peraturan Menteri Kesehatan no 27. Petunjuk teknis sistem Indonesian Case Base Groups (INA- CBGs).2014.
4. Direktorat Jenderal Bina Upaya Kesehatan Kementerian Kesehatan Republik Indonesia. INA-CBGs: Untuk pelayanan rumah sakit lebih baik. Buletin BUK. Mei 2013. 2-3.
5. Fitri A. Analisis perbandingan biaya riil pasien rawat inap terhadap tarif INA-CBG pada program Jamkesmas di RSI Siti Khadijah Palembang [skrpsi]. Palembang: Universitas Sriwijaya; 2012.
6. World Health Organization. Neuropati diabetik menyerang lebih dari 50% penderita diabetes. 2010. diakses melalui www.pdpersi.co.id.
7. Trisnawati KS. Faktor risiko kejadian diabetes melitus tipe II di puskesmas Kecamatan Cengkareng Jakarta Barat Tahun 2012. Jurnal Ilmiah Kesehatan. 2013. 5(1):6-11.
8. Larson M & Anderson GBJ. Partial amputation of the foot for diabetic or ateroscleroticgangrene. J Bone Joint Surg. (60-B). 1978:126-30.
9. American Diabetes Association. Standards of medical care in diabetes care. 2004.
10. Bauer LA. Clinical pharmacokinetic handbook. USA: The McGraw-Hill Companies; 2006.
11. Dipiro. Hand book of pharmacotherapy. 7th Ed.. USA: McGrawHill; 2009.
12. Perkumpulan Endokrinologi Indonesia. Konsensus pengelolaan dan pencegahan diabetes mmelitus tipe 2 di Indonesia. Jakarta: Perkeni; 2011.
13. Surat Edaran Nomor HK/Menkes/32/1/2014. Pelaksanaan pelayanan kesehatan bagi peserta BPJS Kesehatan pada fasilitas kesehatan tingkat pertama dan fasilitas kesehatan tingkat lanjutan dalam penyelenggaraan program jaminan kesehatan. 2014.
14. Peraturan Menteri Kesehatan No. 59. Standar tarif pelayanan kesehatan dalam penyelenggaraan program Jaminan kesehatan. 2014.
15. Arifin I, Praseetyaningrum E, Andayani TM. Evaluasi kerasionalan pengobatan diabetes melitus tipe 2 pada pasien rawat inap di rumah sakit Bhakti Wira Tamtama Semarang tahun 2006. Jurnal Ilmu Farmasi dan Farmasi Klinik. 2007. 4(1).
16. ASKES. Daftar dan plafon harga obat bagi peserta ASKES edisi XXXII periode Januari-Desember 2013. Jakarta: PT.ASKES; 2013.
17. Kementrian Kesehatan Republik Indonesia No. 328/ MENKES/SK/VIII. Formularium Nasional. 2013.
18. Surat Edaran Menteri Kesehatan no. KF/Menkes/167/ III. Pengadaan obat berdasarkan katalog elektrnik (e-catalogue). 2014.
19. BPJS Kesehatan. Addendum perpanjangan DPHO Edisi XXXII tahun 2013 sampai dengan 31 Maret 2014. 2014.
20. Peraturan Presiden no 70. Pengadaan barang atau jasa pemerintah. 2012.
21. Prahasto ID. Kebijakan obat Indonesia yang masih belum memihak pasien: contoh kasus obat generik. Policy Brief. 2010.
Published
2015-04-30
How to Cite
RESTINIA, MITA et al. Drug Treatment Profile among Outpatients of Type 2 Diabetes Melitus after Implemented of JKN. JURNAL ILMU KEFARMASIAN INDONESIA, [S.l.], v. 13, n. 1, p. 63-68, apr. 2015. ISSN 2614-6495. Available at: <http://jifi.farmasi.univpancasila.ac.id/index.php/jifi/article/view/126>. Date accessed: 25 apr. 2024.
Citation Formats
Issue
Vol 13 No 1 (2015): JIFI
Section
Articles
License

Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.

This licence applies to Author(s) and Public Reader means that the users mays :

  • SHARE:
    copy and redistribute the article in any medium or format
  • ADAPT:
    remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication)
  • ALIKE:
    If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original.
  • NO ADDITIONAL RESTRICTIONS:
    You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

It does however mean that when you use it you must:

  • ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

You may not:

  • NONCOMMERCIAL: You may not use the article for commercial purposes.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.